Literature DB >> 20974176

Using the self-administration of apomorphine and cocaine to measure the pharmacodynamic potencies and pharmacokinetics of competitive dopamine receptor antagonists.

Andrew B Norman1, Michael R Tabet, Mantana K Norman, Vladimir L Tsibulsky.   

Abstract

Competitive dopamine receptor antagonists accelerate psychomotor stimulant self-administration. According to pharmacological theory of competitive antagonism antagonists raise the equiactive agonist concentration. In the self-administration paradigm this is assumed to be the satiety threshold or C(min). The magnitude of the proportional increase in satiety threshold (agonist concentration ratio) as a function of antagonist dose should reflect the antagonist pharmacodynamic potency. The time course of this effect should reflect the rate of change of antagonist occupancy of receptors and, therefore, antagonist concentration, i.e. pharmacokinetics. Rats self-administered apomorphine or cocaine at a stable rate and were then injected i.v. with one of four competitive D₁-like or D₂-like dopamine receptor antagonists and the session continued. The agonist concentrations at the time of each self-administration (satiety thresholds) were calculated during the session. The antagonists accelerated self-administration of both agonists with a concomitant increase in the calculated satiety thresholds. The maximum agonist concentration ratio was proportional to the dose of antagonist. The time courses of the changes in agonist concentration ratio were independent of the agonist and of the dose of antagonist. Schild analysis of the maximum agonist concentration ratio as a function of the antagonist dose allowed apparent pA₂ (or K(dose)) to be measured. Antagonist K(dose) values should provide a quantitative basis for receptor identification in behavioral pharmacology. The assay system may also measure the pharmacokinetics of antagonist elimination from the brain. Agonist self-administration represents a sensitive in vivo pharmacological assay system that provides information useful for pharmacokinetic/pharmacodynamic modeling of antagonist effects. Copyright Â
© 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20974176      PMCID: PMC3017394          DOI: 10.1016/j.jneumeth.2010.10.017

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  33 in total

1.  Satiety threshold: a quantitative model of maintained cocaine self-administration.

Authors:  V L Tsibulsky; A B Norman
Journal:  Brain Res       Date:  1999-08-21       Impact factor: 3.252

2.  The receptor concept: pharmacology's big idea.

Authors:  H P Rang
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

3.  Quantification of R-(+)-7-chloro-8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-methyl-3- benzazepine in brain and blood by use of reversed-phase high-performance liquid chromatography with electrochemical detection.

Authors:  C D Kilts; K L Dew; T D Ely; R B Mailman
Journal:  J Chromatogr       Date:  1985-08-09

4.  Fluctuations in nucleus accumbens dopamine concentration during intravenous cocaine self-administration in rats.

Authors:  R A Wise; P Newton; K Leeb; B Burnette; D Pocock; J B Justice
Journal:  Psychopharmacology (Berl)       Date:  1995-07       Impact factor: 4.530

Review 5.  Domperidone: a peripherally acting dopamine2-receptor antagonist.

Authors:  J A Barone
Journal:  Ann Pharmacother       Date:  1999-04       Impact factor: 3.154

6.  Increased lever pressing for amphetamine after pimozide in rats: implications for a dopamine theory of reward.

Authors:  R A Yokel; R A Wise
Journal:  Science       Date:  1975-02-14       Impact factor: 47.728

7.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

8.  Behavioral effects and cerebral pharmacokinetics of apomorphine in the rat: dependence upon the route of administration.

Authors:  M Melzacka; G Wiszniowska; W Daniel; J Vetulani
Journal:  Pol J Pharmacol Pharm       Date:  1979 Jul-Aug

9.  Quantification of SCH 39166, a novel selective D1 dopamine receptor antagonist, in rat brain and blood.

Authors:  J Hietala; T Seppäla; J Lappalainen; E Syvälahti
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

10.  Self-administration of cocaine-heroin combinations by rhesus monkeys: antagonism by naltrexone.

Authors:  J K Rowlett; K M Wilcox; W L Woolverton
Journal:  J Pharmacol Exp Ther       Date:  1998-07       Impact factor: 4.030

View more
  6 in total

1.  Enzyme-therapy approaches for the treatment of drug overdose and addiction.

Authors:  Fang Zheng; Chang-Guo Zhan
Journal:  Future Med Chem       Date:  2011-01       Impact factor: 3.808

2.  The affinity of D2-like dopamine receptor antagonists determines the time to maximal effect on cocaine self-administration.

Authors:  Andrew B Norman; Michael R Tabet; Mantana K Norman; Brittney K Fey; Vladimir L Tsibulsky; Ronald W Millard
Journal:  J Pharmacol Exp Ther       Date:  2011-05-23       Impact factor: 4.030

3.  The dopamine D2 antagonist eticlopride accelerates extinction and delays reacquisition of food self-administration in rats.

Authors:  Jonathon Koerber; David Goodman; Jesse L Barnes; Jeffrey W Grimm
Journal:  Behav Pharmacol       Date:  2013-12       Impact factor: 2.293

4.  Dopamine and Stress System Modulation of Sex Differences in Decision Making.

Authors:  Polymnia Georgiou; Panos Zanos; Shambhu Bhat; J Kathleen Tracy; Istvan J Merchenthaler; Margaret M McCarthy; Todd D Gould
Journal:  Neuropsychopharmacology       Date:  2017-07-25       Impact factor: 7.853

5.  Differential effects of acute and chronic antagonist and an irreversible antagonist treatment on cocaine self-administration behavior in rats.

Authors:  Hanna N Wetzel; Vladimir L Tsibulsky; Andrew B Norman
Journal:  Sci Rep       Date:  2022-05-24       Impact factor: 4.996

6.  Maintained cocaine self-administration is determined by quantal responses: implications for the measurement of antagonist potency.

Authors:  Andrew B Norman; Michael R Tabet; Mantana K Norman; Vladimir L Tsibulsky
Journal:  J Pharmacol Exp Ther       Date:  2013-12-04       Impact factor: 4.030

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.